Haohai Biotec released its interim financial performance with a net income attributable to the parent company of 0.235 billion yuan, a year-on-year increase of 14.64%.

新浪港股 · Aug 18 19:30

Haohai Biotechnology (06826) released a summary of the 2024 interim report, with revenue of CNY 1.404 billion, a year-on-year increase of 6.97%; net income attributable to shareholders of the listed company was CNY 0.235 billion, a year-on-year increase of 14.64%; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was CNY 0.23 billion, a year-on-year increase of 22.66%; basic earnings per share were CNY 1.01/share. It is planned to distribute a cash dividend of CNY 4.00 per 10 shares to all shareholders (including tax).

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more

昊海生物科技发布中期业绩 归母净利润2.35亿元同比增长14.64%

Haohai Biotec released its interim financial performance with a net income attributable to the parent company of 0.235 billion yuan, a year-on-year increase of 14.64%.

Risk Disclaimer

Statement

昊海生物科技发布中期业绩归母净利润2.35亿元同比增长14.64%